NKTI LAB




The Philippines' Leading Clinical Referral Laboratory


Contact Us  |  Careers   |   Site map   |   Search this site  
ISO 15189:2007 Accredited
NKTI main website 
LINKS
NKTI main website 
News



I. REAGENTS EVALUATED IN 2012


SeroDiagnostic Trading
• Albaclone Anti-A Blood Grouping Reagent (Mouse Monoclonal) Direct Agglutinin
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Albaclone Anti-B Blood Grouping Reagent(Mouse Monoclonal) Direct Agglutinin
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Albaclone Anti-D Blend Blood Grouping Reagent (Monoclonal) Direct Agglutinin
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015
Crestline Scientific Corporation

• Spanclone Anti-A Monoclonal
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Spanclone Anti-B Monoclonal
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Spanclone Anti-D (IgG+IgM) Monoclonal
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015
Medical Center Trading Corporation

• Epiclone-2 Anti-D (IgM/IgG) Monoclonal Grouping Reagent
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015
Allied Hospital Supply International Corporation

• Anti-A Cerytec Monoclonal Reagent
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Anti-B Cerytec Monoclonal Reagent
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Anti-D Cerytec Monoclonal Reagent
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015
Meakka Corporation

• Diagast Anti-A (ABO1)
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Diagast Anti-B (ABO2)
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Diagast Anti-D (RH1) TOTEM
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015
Biocare Health Resources

• Anti-A Series 1 (Murine Monoclonal)
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Anti-B Series 3 (Murine Monoclonal) Typing Sera
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Anti-D Series 5 (Monoclonal Blend) Typing Sera
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015
Sterilab Company

• Accucare Anti-A Monoclonal (IgM) Blood Grouping Sera
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Accucare Anti-B Monoclonal (IgM) Blood Grouping Sera
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

• Accucare Anti-D Monoclonal (IgG/IgM) Blood Grouping Sera
Effectivity date: April 1, 2013 to March 31, 2018
Re-evaluation due date: January 2015

II. ADDITIONAL REAGENTS EVALUATED AS OF NOVEMBER 2014
Johnson & Johnson (Phils.), Inc.

• Bioclone Anti-A (Murine Monoclonal Blend) Blood Grouping Reagent (Reference Code:711220)
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Bioclone Anti-B (Murine Monoclonal Blend) Blood Grouping Reagent Anti-B (Reference code: 711320)
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Bioclone Anti-D (Anti-Rh) (Monoclonal-Polyclonal Blend) Anti-D (Anti-Rho) Blood Grouping Reagent (Reference code: 717380)
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Biovue ABD Confirmation
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017
Medicotek Inc.

• Eryclone Anti-A Monoclonal Blood Grouping Antibodies
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Eryclone Anti-B Monoclonal Blood Grouping Antibodies
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Rhofinal Anti-D (Rho) (IgM+IgG) Monoclonal Blood Grouping Antibodies
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017
Biocare Health Resources

• Immunoclone Anti-A Galileo IgM Typing Sera (Murine Monoclonal)
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Immunoclone Anti-B Galileo IgM Typing Sera (Murine Monoclonal)
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• ImmunocloneR Anti-D rapid Galileo (IgM) (Human Monoclonal)
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017
Meakka Corporation

• Diagast ABD-Lys
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017
Lifeline Diagnostics Supplies, Inc.

• Diaclon ID Card for ABD confirmation for patients / REFERENCE CODE 001254
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Diaclon ID Card for ABD confirmation for donors / REFERENCE CODE 001134
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Diaclon ID Card Type+Screen Typing Sera (Monoclonal Antibodies)
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Diaclon ID Card Complete Crossmatch
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Diaclon ID Card ABO / D + Reverse Grouping for Patients
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Diaclon ABO/Rh for Newborns DVI-Blood Typing Sera
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Diaclon Anti-A
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Diaclon Anti-B Blood Typing Sera (Monoclonal IgM Antibody)
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Diaclon Anti-D Blood Typing Sera (Monoclonal IgG and IgM Antibodies)
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

• Diaclon Anti-AB Blood Typing Sera
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017
Medical Center Trading Corporation

• Epiclone Anti-A/B Monoclonal Grouping
Effectivity date: November 1, 2014 to October 31, 2019
Re-evaluation due date: January 2017

III. ADDITIONAL REAGENTS EVALUATED AS OF AUGUST 14, 2015

Value-Rx, INC.
• Anti-A Blood Typing Sera (A-Mono-11H5-10) (Initial), BHDT-R-2013-3475
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Anti-B Blood Typing Sera (B- Mono-6F9-10) (Initial), BHDT-R-2013-3474
Effectivity date: August 2015 to July 2020
Re-evaluation due date: August 2018

• Anti-D Blood Typing Sera (D-Mono Blend TH-10 (Initial), BHDT-R-2014-06
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

MRL Cybertec Corp.
• Invitroclone Anti- A monoclonal Blood Typing Antibodies (Initial), BHDT-R-2012-1867
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Invitroclone Anti- B monoclonal Blood Typing Antibodies (Initial), BHDT-R-2012-1868
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Invitroclone Anti- AB monoclonal Blood Typing Antibodies (Initial), BHDT-R-2012-1867
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

Serodiagnostic Trading
• Diagast Anti-AB Blood Typing Sera (Initial), BHDT-R-2013-1880
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Diagast Groupa 2 Lys (Initial), BHDT-2013-3801
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Albaclone Anti-A Direct Agglutinin (Renewal), CDRRHR-RAR 14-427
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Albaclone Anti-B Direct Agglutinin (Renewal). CDRRHR-RAR 14-426
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Albaclone Anti-D Direct Agglutinin (Renewal). CDRRHR-RAR 14-425
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

Lifeline Diagnostics Supplies, Inc.
• Diaclone ABO/Rh for Newborn DVI (+) (Initial) BHDT-12-2013-4185
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

A.M.I Equipment Services and solutions
• Human Huma type Anti-A Reagent (Initial) BHDT R-2013-1789
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Human Huma type Anti-B Reagent (Initial) BHDT R-2013-1792
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Human Huma type Anti- D (IgM)Reagent (Initial) BHDT R-2013-1991
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

Medical Center Trading Corp.
• Epiclone TM Anti-A Monoclonal Blood Group Reagent (IgM) BHDT R-2013-3065
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• Epiclone TM Anti-B Monoclonal Blood Group Reagent (IgM) BHDT R-2013-3066
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

Trulaboratories Corp.
• TruseraTM Anti-A Monoclonal Reagent (Initial) BHDT R-2014-2633
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• TruseraTM Anti-B Monoclonal Reagent (Initial) BHDT R-2014-2634
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

• TruseraTM Anti-D Monoclonal Reagent (Initial) BHDT R-2014-2635
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

Johnson and Johnson(Phils) Inc.
• Orthobiovue System ABO-Rh Reverse Casette (Initial) BHDT R-2015-007
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018

Labmate Pharma Inc.
• Erycard 2.0 Blood Grouping card for ABO/Rho (D) Forward grouping with Autocontrol BHDT R-2013-3961
Effectivity date: August 2015 to July 2020
Re-evaluation due date: July 2018
  
Immunohematology National Reference Laboratorymore
Osmolality Determination by Freezing Point Depressionmore
GSK Diagnostic Soft Tissue Sarcoma Histopathology Workshop
NKTI pathologist shares expertise on kidney tumor
more

QuantiFERON TB Gold
Interferon Gamma Release Assay (IGRA)

more

CYSTATIN C SERUM LEVEL
TEST AVAILABILITY

by: Mary Ann A. Aytona, RMT

more

VITAMIN D SERUM LEVEL
TEST AVAILABILITY

by: Mary Ann A. Aytona, RMT

more

QUANTIFERON-TB GOLD ASSAY
NOW AVAILABLE
by Ma. Clarissa G. Dela Cruz, RMT

more
NKTI holds voluntary blood donation drive
by Mark Anthony C. Turingan, M.D.
more
The NKTI 7th KABALIKAT AWARDS
by Suzette G. Tañada, RMT Chief Medical Technologist Hematology and Transfusion Medicine Division
more
Optimum Savings on Laboratory Test Packages
Norely B. Gil June 17, 2013
more
1234

National Kidney and Transplant Institute, East Avenue Quezon City Philippines 1100